Hyperdiploidy is less frequent inAL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)

Blood

Volumn 117, Issue 14, 2011, Pages 3809-3815

  Bochtler, Tilmann ^a   Hegenbart, Ute ^a   Heiss, Christiane ^b   Benner, Axel ^b   Moos, Marion ^a   Seckinger, Anja ^a   Pschowski Zuck, Stephanie ^c   Kirn, Désirée ^c   Neben, Kai ^a   Bartram, Claus R ^c   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a,b   Hose, Dirk ^a   Jauch, Anna ^c   Schonlandl, Stefan O ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 1Q; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CYTOGENETICS; DIPLOIDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMACYTOSIS; PRIORITY JOURNAL; CHROMOSOME 11; CHROMOSOME 14; COHORT ANALYSIS; COMPARATIVE STUDY; GENE FREQUENCY; GENE TRANSLOCATION; GENETICS; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; COHORT STUDIES; DIPLOIDY; FEMALE; GENE FREQUENCY; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; TRANSLOCATION, GENETIC;

EID: 79953818145     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-268987     Document Type: Article

References (45)

1. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333-6338. (Pubitemid 46218843)
2. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106(1):296-303. (Pubitemid 40967205)
3. Chng WJ, Kumar S, Vanwier S, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007; 67(7):2982-2989. (Pubitemid 46724834)
4. Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011;117(2):553-562.
5. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569. (Pubitemid 34438817)
6. Rasillo A, Tabernero MD, Sanchez ML, et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer. 2003; 97(3):601-609. (Pubitemid 36125837)
7. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001;98(3):714-720.
8. Lee W, Han K, Drut RM, Harris CP, Meisner LF. Use of fluorescence in situ hybridization for retrospective detection of aneuploidy in multiple myeloma. Genes Chromosomes Cancer. 1993;7(3): 137-143. (Pubitemid 23194422)
9. Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood. 1995;86(10):3915-3921.
10. Brousseau M, Leleu X, Gerard J, et al. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients. Clin Cancer Res. 2007;13(20):6026- 6031. (Pubitemid 350075058)
11. Wuilleme S, Robillard N, Lode L, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005;19(2):275-278. (Pubitemid 40220593)
12. Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005;106(6):2156-2161. (Pubitemid 41291733)
13. Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001; 98(7):2266-2268.
14. Perfetti V, Coluccia AM, Intini D, et al. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol. 2001; 158(5):1599-1603. (Pubitemid 32422924)
15. Harrison CJ, Mazzullo H, Ross FM, et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 2002;117(2):427-435. (Pubitemid 34451161)
16. Bochtler T, Hegenbart U, Cremer FW, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood. 2008;111(9):4700-4705.
17. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546-1558. (Pubitemid 38235629)
18. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13(3):300-309. (Pubitemid 17204708)
19. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140(2):85-93.
20. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc. 1999;74(5):490-494.
21. Bochtler T, Hegenbart U, Heiss C, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica. 2008;93(3):459-462. (Pubitemid 351398651)
22. Hillengass J, Zechmann CM, Nadler A, et al. Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma. Int J Cancer. 2008;122
23. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489-3495. (Pubitemid 46572539)
24. Agnelli L, Fabris S, Bicciato S, et al. Up-regulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol. 2007;136(4): 565-573. (Pubitemid 46148193)
25. Chiecchio L, Dagrada GP, Ibrahim AH, et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica. 2009;94(12):1708-1713.
26. Holm AI, Kohler B, Hoffmann SV, Nielsen SB. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65-70.
27. von Heydebreck A, Gunawan B, Fuzesi L. Maximum likelihood estimation of oncogenetic tree models. Biostatistics. 2004;5(4):545-556. (Pubitemid 41180204)
28. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985;39:783-791.
29. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404-413.
30. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. www.R-project.org. Accessed August 24, 2009.
31. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stemcell transplantation. Blood. 2006;108(5):1724-1732. (Pubitemid 44316143)
32. Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer. 2005;44(2):194-203. (Pubitemid 41306648)
33. Smadja NV, Leroux D, Soulier J, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer. 2003;38(3):234-239. (Pubitemid 37259640)
34. Gutierrez NC, Garcia JL, Hernandez JM, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood. 2004;104(9):2661-2666. (Pubitemid 39434945)
35. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20(9):1610-1617. (Pubitemid 44264105)
36. Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102(7):2562-2567. (Pubitemid 37193596)
37. Chng WJ, Santana-Davila R, Van Wier SA, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006;20(5):807-813.
38. q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99(6):2185-2191. (Pubitemid 34525505)
39. Bryce AH, Ketterling RP, Gertz MA, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009; 94(3):380-386.
40. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98(7): 2229-2238.
41. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients: Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol. 1995;90(1):106-112.
42. Chng WJ, Ketterling RP, Fonseca R. Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. Genes Chromosomes Cancer. 2006;45(12):1111-1120. (Pubitemid 44763439)
43. q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11): 2034-2040. (Pubitemid 44614894)
44. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-2221.
45. Zandecki M, Lai JL, Genevieve F, et al. Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. Blood. 1997;90(9):3682-3690 BLOOD, (Pubitemid 27473439)